An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA - Wikidata - awgldk - TriplyDB

An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA

An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA

http://www.wikidata.org/entity/Q28204816

about

sameAs

Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism Alternative splicing for diseases, cancers, drugs, and databases High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice Doxycycline-controlled splicing modulation by regulated antisense U7 snRNA expression cassettes Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.Splicing of the Survival Motor Neuron genes and implications for treatment of SMA Assays for the identification and prioritization of drug candidates for spinal muscular atrophy Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay.A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo.Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation.Therapeutic strategies for the treatment of spinal muscular atrophy.Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy.In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes.SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice.Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds Discovery, synthesis, and biological evaluation of novel SMN protein modulators.Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene.Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA.P-coumaric acid regulates exon 12 splicing of the ATP7B gene by modulating hnRNP A1 protein expressions.Splicing inhibition of U2AF65 leads to alternative exon skipping.Therapy development for spinal muscular atrophy in SMN independent targets.Altered mRNA Splicing in SMN-Depleted Motor Neuron-Like Cells.A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.Spinal muscular atrophy: an update on therapeutic progress Targeting RNA-splicing for SMA treatment.Progress in therapeutic antisense applications for neuromuscular disorders.Spinal muscular atrophy disease: a literature review for therapeutic strategies.Developments in the discovery of drugs for spinal muscular atrophy: successful beginnings and future prospects.Alternative splicing of in-frame exon associated with premature termination codons: implications for readthrough therapies.A double-reporter splicing assay for determining splicing efficiency in mammalian cells.

P2860

Q24613087-A5FA33C8-5164-45AB-B647-F1F18EA567A1 Q26852848-6EAA9B7B-1B7B-4510-9056-4E906A0657C0 Q27311317-D1069EBC-1972-4EBD-83DF-1977B01B143D Q28290763-8AE0FD22-4075-434C-8B80-818F0419668F Q28472268-CD14BF73-319B-49A6-8456-DB18CEE5E5E5 Q30492560-AE12CF11-CAC3-4110-9B03-410AE47AB328 Q30493891-7B2CFD19-936F-4C67-86E9-4111820E4A6B Q30540653-07A6E68F-FB06-4C76-AE4F-D88BB13013F6 Q30828907-4D1FE948-08C9-4517-812A-B0FFE28CA1E1 Q33357493-6697A64F-3F59-4B5E-AE20-5C38A5ED0707 Q33393896-592F6602-D1C8-4427-B3CC-169C580694E9 Q33853846-290E10C9-0A1A-47A1-A43D-40CD25012663 Q34065993-EAACB504-657D-4C27-9D44-72FA2D982DA0 Q34082155-C97E2C32-1A70-40D3-A4E9-B80C845982A2 Q34123129-48C4967D-0B47-491B-94C7-C40450D24D24 Q34132150-6BC7B43B-5FAB-4B49-AA52-8DBF0C0FEC08 Q34166299-C27B5607-F04A-4276-878B-030104A127AF Q34296140-52EEA70E-4682-413A-A1E2-F0BA27700A8E Q34314191-C449D52F-F4D8-4AAE-8D1C-C80C4A2A5C66 Q34365948-B5AC98A3-9D91-4F7B-93C5-34405DA963C6 Q34478749-61621BA8-F9AA-4E44-BD8B-1B1A3106E65F Q34760255-5C9A9754-C00F-457F-943D-6A098F6D9C06 Q35216315-F4C4F042-A5A2-4B4E-9874-FE357AE3FAD2 Q35221624-AC62241E-4603-4FD4-B80F-360A89763823 Q35567374-E34AE848-4BE4-41A7-BAA0-40660D236574 Q35683524-826F0073-B8BA-4E53-85E7-F7D09E972EC8 Q35850907-E5EB5560-AEE7-4FC6-8C00-F4E5ADFDF347 Q35961240-F1188BE3-1C9B-46FE-9FB9-61AF481FBC45 Q36014761-8ACE2EA0-A0E5-4797-BD07-F8EEDD4F7D56 Q36162571-43FD879C-9E19-41AC-8105-2C23818004CD Q36323111-9CF76D91-683D-4875-84A1-F4593B026054 Q36718923-C2DBFE1D-6CDA-4FED-BAD0-C3C0FDEC1244 Q37035709-55B5FD2E-F3CE-404E-8401-8D68CAF75ACF Q37302832-1A8A0852-22A2-450D-A726-CE92213A5A1D Q37461458-4BBA95DB-2BA8-4ED4-AA4C-53D58BE9BA9E Q37609948-C02D5C82-44C5-4F72-995D-2E86ABCC7914 Q37714861-EB327B89-1DDE-4766-90D2-B34E556EB478 Q38014955-4F808EB6-642B-4B18-B378-C0BAC51C7C50 Q39259322-CAEBD2B9-B2C9-4FFA-AC9E-62352D4395C9 Q40150084-C0E02E06-68DE-4A5A-AC87-F738E56F4627

P2860

An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA

http://www.wikidata.org/entity/Q28204816

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@ast

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@en

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@nl

type

label

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@ast

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@en

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@nl

prefLabel

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@ast

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@en

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@nl

P1433

Q28204816-D7906C6E-D27E-4C03-BC95-6F38B0968EFA

P1476

Q28204816-FDF022A1-0203-4866-B9EA-FC465031464D

P2093

Q28204816-001FAD65-CE76-48F2-B566-78A2E00EE247

Q28204816-5D3FEE14-21EA-492C-8F12-1D5F8F98E1EA

Q28204816-6B6B0439-4AF4-45C3-8376-243F428552C5

Q28204816-DB345E8D-AAA5-42A1-A9D6-3A5C9F5665C4

P2860

Q28204816-014CEC7B-EDC4-43FA-A5E8-EA3C9A4A2CC7

Q28204816-03B9BBD7-68BF-4A43-82D2-DC740F1C924E

Q28204816-41835617-6C32-4AF9-9252-9A16BAC22993

Q28204816-5C0575A4-7FCE-47FF-9B21-87B4FD01A2D3

Q28204816-5D2FF090-BEFC-4228-A1B6-297268827621

Q28204816-60E6B976-AD63-42A4-B270-F7FA981EC1DD

Q28204816-634E7FA9-E63B-4CC9-99F5-8DBDFE8E4614

Q28204816-77B86204-2C32-4A56-815B-69A13C3DAE4E

Q28204816-7FC9AABC-D7F1-43F5-A913-FCBAD24E87D2

Q28204816-A01304CB-E3DF-4446-BD22-E2032100B169

P2888

Q28204816-866FC24E-41BB-4827-A73D-36CCF8E3EA0C

P304

Q28204816-6720884C-C68D-478B-9717-E1760692985A

P31

Q28204816-69C492DC-6912-4B83-B3DC-DABBB8689BF8

P3181

Q28204816-4BBE919B-2BC0-42B8-A39A-8D86F328D6BC

P356

Q28204816-C4E0AF37-5D55-43A5-B02B-55B90B5AFED2

P407

Q28204816-B5F35B76-EEE0-4E0A-AFCC-0D437477C8E2

P433

Q28204816-3FAF18D2-82D3-4CED-B8F7-F858A632F956

P478

Q28204816-C6229D0B-49FB-4C94-B877-7A2291742744

P577

Q28204816-34458BD4-3FD5-4D74-B1F5-B5546252A360

P5875

Q28204816-8AFF3666-390E-4572-A9CB-915CA9104F91

P698

Q28204816-72D1B7CF-8479-4B70-B211-D32D3E976971

P3181

P356

P1433

P1476

An in vivo reporter system for ...... mRNA: potential therapy of SMA

@en

P2093

C L Lorson

http://www.w3.org/2001/XMLSchema#string

E J Androphy

http://www.w3.org/2001/XMLSchema#string

J Zhou

http://www.w3.org/2001/XMLSchema#string

M L Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Spinal muscular atrophy

Identification and characterization of a spinal muscular atrophy-determining gene

A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy

A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients.

The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements

Structure and organization of the human survival motor neurone (SMN) gene.

Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system.

Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)

Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy.

P2888

P304

1532-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3004401

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.GT.3301550

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11649713

http://www.w3.org/2001/XMLSchema#string

P698

11704813

http://www.w3.org/2001/XMLSchema#string